로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Claudin 18.2 Hot |FMC 63 Ab  |FcRn
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: 홈 > Licensing
License
Introduction

bioSeedin, one of the most preeminent asset management, public relations, and financial advisory firms for biotech and pharmaceutical companies in APAC, operates across North America, Europe, and Asia.

The firm provides asset management services via licensing in and out, co-developmental partner sourcing, and project implementation, as well as advising on public relation management, Asia market entry, investment strategy, mergers and acquisitions, and capital raising.

I have projects to LICENSE OUT
I want to LICENSE IN OTHER projects
Hot projects
Active

SN-38 Polymeric Nanoparticle (new formulation)

Preclinical
PH1
PH2
PH3
  • Indications: Solid Tumor (Lung Cancer)
  • Cooperation demands: Global and Regional Out-licensing
License In
Follow
Active

Viscous Gel Temozolomide

Preclinical
PH1
PH2
PH3
  • Indications: Glioblastoma
  • Cooperation demands: license-out or co-development Globally except in CIA
License In
Follow
Active

EED inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: Hematological malignancy and Solid tumors
  • Cooperation demands: License-out or co-development
License In
Follow
Active

ActRIIB inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: Cancer cachexia
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Anti-GCC humanized antibody

Preclinical
PH1
PH2
PH3
  • Indications: Solid Tumor (Colorectal, gastric and esophageal cancers）
  • Cooperation demands: sequence authorization or project transfer
License In
Follow
Active

CCR8 Humanized Antibody

Preclinical
PH1
PH2
PH3
  • Indications: Solid tumor
  • Cooperation demands: sequence authorization or project transfer
License In
Follow
Active

FRα BsAb-ADC

Preclinical
PH1
PH2
PH3
  • Indications: Ovarian cancer
  • Cooperation demands: sequence authorization or project transfer
License In
Follow
Active

B7-H3×CD3 BsAb for solid tumor

Preclinical
PH1
PH2
PH3
  • Indications: Solid tumor
  • Cooperation demands: License-out or co-development
License In
Follow
Active

PD-1×TIGIT BsAb for Advanced solid tumor

Preclinical
PH1
PH2
PH3
  • Indications: Advanced solid tumor
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Her2xCD3 BsAb

Preclinical
PH1
PH2
PH3
  • Indications: HER2+ Cancer
  • Cooperation demands: License-out and co-development
License In
Follow
Active

A2aR/A2bR Antagonist

Preclinical
PH1
PH2
PH3
  • Indications: Advanced/metastatic solid tumors or hematological malignancies
  • Cooperation demands: License-out (Ex-China) or co-development
License In
Follow
Active

GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia

Preclinical
PH1
PH2
PH3
  • Indications: NASH, T2DM, Hyperlipoidemia
  • Cooperation demands: License-out or co-development the global right
License In
Follow
Active

PI3K/mTOR dual inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: Idiopathic pulmonary fibrosis (IPF) and solid tumor, (FDA ODD）
  • Cooperation demands: License-out or co-development
License In
Follow
Active

HIF-PHs inhibitor for CKD and Renal anemia

Preclinical
PH1
PH2
PH3
  • Indications: CKD and Renal anemia
  • Cooperation demands: License-out or co-development of the global right (except for China)
License In
Follow
Active

NF-kB inhibitor (Novel small molecule drug) for cancer cachexia

Preclinical
PH1
PH2
PH3
  • Indications: Cancer Cachexia
  • Cooperation demands: License-out or co-development the global right
License In
Follow
Active

Oxazolidone (new compounds) antibiotics

Preclinical
PH1
PH2
PH3
  • Indications: bacterial infections caused by specific microbial sensitive strains, such as complex or non-complex skin and skin soft tissue infections, community/hospital acquired pneumonia, vancomycin-resistant enterococcal infections, other bone and joint infections,
  • Cooperation demands: License-out or co-development the global right
License In
Follow
Active

High selective OX1R/OX2R dual inhibitor treating insomnia

Preclinical
PH1
PH2
PH3
  • Indications: Insomnia
  • Cooperation demands: License-out or co-development the global right
License In
Follow
Active

ACC inhibitor treating NASH

Preclinical
PH1
PH2
PH3
  • Indications: NASH
  • Cooperation demands: License-out or co-development the global right
License In
Follow
Active

FXR Agonist

Preclinical
PH1
PH2
PH3
  • Indications: Diabetic kidney disease
  • Cooperation demands: Out licensing global right
License In
Follow
Active

SGLT2 inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: Diabetes
  • Cooperation demands: Out licensing global right
License In
Follow
Active

FXR Agonist

Preclinical
PH1
PH2
PH3
  • Indications: NASH
  • Cooperation demands: License-out or co-development
License In
Follow
Active

XO/URAT1 Dual target inhibitors for HUA

Preclinical
PH1
PH2
PH3
  • Indications: Hyperuricemia (HUA)
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Anti-B7H3 ADC

Preclinical
PH1
PH2
PH3
  • Indications: Broad cancer
  • Cooperation demands: License-out or co-development the global right
License In
Follow
Active

sGC stimulator

Preclinical
PH1
PH2
PH3
  • Indications: Pulmonary arterial hypertension (PAH), Chronic thromboembolic pulmonary hypertension (CTEPH), Heart failure with reduced ejection fraction (HFrEF), Chronic kidney disease (CKD)
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Reversible MAOB Inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: Parkinson's disease
  • Cooperation demands: License-out or co-development
License In
Follow
Active

A SSRI & Partial 5-HT1A Agonist

Preclinical
PH1
PH2
PH3
  • Indications: Depression
  • Cooperation demands: License-out or co-development
License In
Follow
Active

RET high selective inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: NSCLC, Medullary thyroid cancer, Thyroid cancer
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Capsid Assembly Inhibitors for HBV

Preclinical
PH1
PH2
PH3
  • Indications: HBV
  • Cooperation demands: License-out or co-development
License In
Follow
Active

PI3Kδ inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: Hematologic malignancies
  • Cooperation demands: License-out and co-development
License In
Follow
Active

Capsid Assembly Inhibitors for HBV

Preclinical
PH1
PH2
PH3
  • Indications: HBV
  • Cooperation demands: License-out or co-development
License In
Follow
Active

NCE for the treatment of IPF

Preclinical
PH1
PH2
PH3
  • Indications: Idiopathic Pulmonary Fibrosis (IPF)
  • Cooperation demands: License-out or co-development
License In
Follow
Active

FLT3 Inhibition

Preclinical
PH1
PH2
PH3
  • Indications: FLT3-ITD mutation AML
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Anti-Her2 II / Anti-Her2 IV Bi-specific antibody ADC

Preclinical
PH1
PH2
PH3
  • Indications: Solid tumor
  • Cooperation demands: License-out or co-development
License In
Follow
Active

EGFR inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: Esophageal Carcinoma and Pancreatic Cancer
  • Cooperation demands: License-out or co-development for the global right and Clinical development in the US or EU (PK and Phase III)
License In
Follow
Active

5-HT1F agonist

Preclinical
PH1
PH2
PH3
  • Indications: Migraine
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Orexin Receptor Antagonist (OX1R and OX2R)

Preclinical
PH1
PH2
PH3
  • Indications: Insomnia Disorder
  • Cooperation demands: License-out or co-development
License In
Follow
Active

PEGylation CD3 + CD19 bsAb

Preclinical
PH1
PH2
PH3
  • Indications: Autoimmune disease
  • Cooperation demands: License-out or co-development
License In
Follow
Active

DHODH inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: IBD, expanded indication COVID-19
  • Cooperation demands: License-out or co-development
License In
Follow
Active

c-Met/AXL inhibitor

Preclinical
PH1
PH2
PH3
  • Indications: Gastric cancer, solid tumor
  • Cooperation demands: License-out or co-development
License In
Follow
Active

LAG-3 mAb

Preclinical
PH1
PH2
PH3
  • Indications: Advanced solid tumors
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Claudin18.2×CD8+ T bsAb

Preclinical
PH1
PH2
PH3
  • Indications: gastric cancer, pancreatic cancer, lung cancer
  • Cooperation demands: License-out or co-development
License In
Follow
Active

SIRPα×PD-1 bsAb

Preclinical
PH1
PH2
PH3
  • Indications: broad cancer
  • Cooperation demands: License-out or co-development
License In
Follow
Active

TIM3×PD-1 bsAb

Preclinical
PH1
PH2
PH3
  • Indications: Solid Tumor
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Claudin18.2 mAb

Preclinical
PH1
PH2
PH3
  • Indications: Gastric cancer, Pancreatic cancer
  • Cooperation demands: License-out or co-development
License In
Follow
Active

CD40 mAb

Preclinical
PH1
PH2
PH3
  • Indications: Advanced solid tumors
  • Cooperation demands: License-out or co-development
License In
Follow
Active

IL10 / IL10RA mAb

Preclinical
PH1
PH2
PH3
  • Indications: Sepsis/ HLH/ CRS
  • Cooperation demands: License-out or co-development
License In
Follow
Active

CD19+CD37 CAR-T

Preclinical
PH1
PH2
PH3
  • Indications: NHL, Leukemia
  • Cooperation demands: License-out or co-development
License In
Follow
Active

CD47 Monoclonal Antibody

Preclinical
PH1
PH2
PH3
  • Indications: Hematologic tumors, solid tumors
  • Cooperation demands: License-out or co-development
License In
Follow
Active

CD37+CD22 CAR-T

Preclinical
PH1
PH2
PH3
  • Indications: Hematological malignancies (leukemia, multiple myeloma, lymphoma)
  • Cooperation demands: License-out or co-development
License In
Follow
Active

Trop2 ADC

Preclinical
PH1
PH2
PH3
  • Indications: “hard-to-treat” solid tumors (pancreatic, gastric, etc)
  • Cooperation demands: License-out or co-development
License In
Follow
Active

NGF mAb

Preclinical
PH1
PH2
PH3
  • Indications: Cancer pain, chemotherapy-induced neuropathic pain, Kashin-Beck disease, diabetic neuralgia, interstitial cystitis, chronic low back pain.
  • Cooperation demands: License-out or co-development
License In
Follow
Active

B7H3×PD-L1 bsAb

Preclinical
PH1
PH2
PH3
  • Indications: B7H3+ and PD-L1+/low cancer
  • Cooperation demands: License-out or co-development
License In
Follow
Active

CD19 mAb

Preclinical
PH1
PH2
PH3
  • Indications: Autoimmune diseases/ B cell malignancies
  • Cooperation demands: License-out or co-development
License In
Follow
Active

BAFFR×CD3 bsAb

Preclinical
PH1
PH2
PH3
  • Indications: B cell malignancies/ autoimmune diseases
  • Cooperation demands: License-out or co-development
License In
Follow
Active

TIGIT-Fc protein

Preclinical
PH1
PH2
PH3
  • Indications: Advanced solid tumors, especially those with high expression of CD155
  • Cooperation demands: Project authorization, transfer or co-development.
License In
Follow
Active

Anti-PD-L1 / TIGIT bispecific antibody

Preclinical
PH1
PH2
PH3
  • Indications: NSCLC, SCLC, multiple myeloma, liver cancer, triple negative breast cancer, pancreatic cancer, etc.
  • Cooperation demands: Project authorization, transfer or co-development.
License In
Follow
Active

Antagonizing TSP1/CD36 Polypeptide Blocking the activation of TGF-β1

Preclinical
PH1
PH2
PH3
  • Indications: Progressive Fibrosis Interstitial Lung Disease (PF-ILD), Solid Tumor.
  • Cooperation demands: Out-licensing outside the Great China
License In
Follow
Active

PD-1/CD80 bispecific antibody

Preclinical
PH1
PH2
PH3
  • Indications: Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer.
  • Cooperation demands: Project transfer or co-development. (the project’s company is in the startup stage and seek external cooperation to accelate drug research and development.)
License In
Follow
Active

Target 4-1BB monoclonal antibody

Preclinical
PH1
PH2
PH3
  • Indications: Tumors such as breast cancer, bladder cancer, NSCLC,DLBCL.
  • Cooperation demands: Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)
License In
Follow
Active

Anti-LAG-3 monoclonal antibody

Preclinical
PH1
PH2
PH3
  • Indications: Tumors such as melanoma, non-small cell lung cancer,liver cancer, gastric carcinoma
  • Cooperation demands: Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)
License In
Follow
Active

Anti-TIM-3 monoclonal antibody

Preclinical
PH1
PH2
PH3
  • Indications: Tumors such as lung cancer,liver cancer, gastric carcinoma, cervical cancer, prostate cancer.
  • Cooperation demands: Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)
License In
Follow

This web search service is supported by Google Inc.

totop
Call us
우리에게 전화하세요
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Email
이메일
order.kr@acrobiosystems.com
Fax
팩시
+1 888-377-6111
Address
주소
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

대글

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap